Sun, Dec 21, 2014, 8:04 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • tuna_20_25 tuna_20_25 Oct 30, 2013 1:10 AM Flag

    LOXO and ARRY

    Loxo Oncology, Inc., a biopharmaceutical company focused on targeted cancer therapies for genetically-defined populations, announced today that its lead clinical program is a potent and selective inhibitor of the Trk family of receptor tyrosine kinases. Loxo Oncology acquired rights to this program from Array Biopharma (NASDAQ:ARRY), which had pursued a multi-year discovery effort to design purpose-built compounds that spare structurally similar kinase targets, such as ALK, JAK and VEGF.


4.86+0.06(+1.25%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.